Novo Nordisk Streamlines Operations as Oral Wegovy Data Reinforce Obesity Strategy
Novo Nordisk sells Parkinson’s candidate to focus on metabolic drugs; oral Wegovy shows 21.6% weight loss at 64…
Novo Nordisk Streamlines Metabolism Focus as Menopause Data and Analyst Upgrade Signal Turnaround
Novo Nordisk sheds last cell therapy asset to focus on metabolic diseases, as Hedgeye predicts 52-117% upside and…